NCT03093909
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 12 Years to 50 Years (Child, Adult)
Location of Metastases: Lung
Additional Notes:
Exclusions:
https://ClinicalTrials.gov/show/NCT03093909